title: [Dabigatran eteksilat  new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
authors: E P
authors: EP
authors: Panchenko
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000379:methods*; D000069604:Dabigatran; D016903:Drug Monitoring / Q000379:methods*; D006439:Hemodynamics; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000503:physiopathology; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran